Flexipharm Austrading's vision is to become a UK-based specialty pharmaceutical company that is genuinely respected and trusted by NHS hospitals. It was founded in 2018 by Michael Clark, an experienced specialty pharmaceutical company founder and board director. Flexipharm Austrading has a singular focus on commercialising established molecules embedded in hospital use where there are concerns around security of ongoing supply; where the current presentation is not optimal for the needs of the NHS staff; and where the current presentations can contribute to medication errors. The Company has a deep understanding of the conditions where its medicines are used and builds enduring meaningful dialogue with the NHS staff involved in using these medicines. It works in partnership with Phebra Pty Ltd, an Australian pharmaceutical company developing and manufacturing injectable pharmaceutical products. For further information visit www.flexipharmaustrading.com.
SOURCE Flexipharm Austrading

www.flexipharmaustrading.com

Flexipharm Austrading

Phebra is an Australian based specialty pharmaceutical group which develops, manufactures and markets critical medicines across the world.

www.phebra.com

Phebra

Leading Australian pharmaceutical group Phebra Holdings ('Phebra') is pleased to announce that it has completed a share purchase agreement with the UK hospital specialty pharmaceutical company Flexipharm Austrading Limited ('FAL').

Phebra Acquires Equity Stake In Uk Specialty Hospital Pharma Company Flexipharm Austrading

Description

Company Information

M&A Insights

Phebra Acquires Equity Stake In Uk Specialty Hospital Pharma Company Flexipharm Austrading

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

M&A Insights

Company Information